ストックスクリーナーアプリを入手
13.51
5.33%
-0.76
プレマーケット:
13.51
前日終値:
$14.27
開ける：
$14.52
24時間の取引高:
1.02M
Relative Volume:
1.48
時価総額：
$737.60M
収益：
$8.78M
当期純損益:
$-104.70M
株価収益率:
-5.7004
EPS:
-2.37
ネットキャッシュフロー:
$-82.68M
1週間 パフォーマンス:
+9.39%
1か月 パフォーマンス:
+17.38%
6か月 パフォーマンス:
+27.21%
1年 パフォーマンス:
-5.39%
1日の値動き範囲:
$13.15
$14.71
1週間の範囲:
$12.26
$14.78
52週間の値動き範囲:
$5.35
$16.15
Stoke Therapeutics Inc Stock (STOK) Company Profile
STOK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
13.51 | 740.88M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-18 | 開始されました | Jefferies | Buy |
| 2024-12-20 | 開始されました | Chardan Capital Markets | Buy |
| 2024-10-14 | 再開されました | Leerink Partners | Outperform |
| 2024-03-26 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-07-25 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | アップグレード | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 再開されました | Canaccord Genuity | Buy |
| 2023-01-06 | ダウングレード | BofA Securities | Buy → Underperform |
| 2022-10-24 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 開始されました | Jefferies | Buy |
| 2021-12-03 | 開始されました | BofA Securities | Buy |
| 2021-11-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 開始されました | UBS | Neutral |
| 2021-05-10 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-02-10 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-12-15 | 再開されました | H.C. Wainwright | Buy |
| 2020-12-11 | 繰り返されました | Needham | Buy |
| 2020-10-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 再開されました | JP Morgan | Neutral |
| 2020-09-29 | 開始されました | Needham | Buy |
| 2019-12-18 | 開始されました | Wedbush | Outperform |
| 2019-11-12 | 開始されました | BTIG Research | Buy |
| 2019-10-25 | 開始されました | H.C. Wainwright | Buy |
| 2019-07-15 | 開始されました | Canaccord Genuity | Buy |
| 2019-07-15 | 開始されました | Cowen | Outperform |
| 2019-07-15 | 開始されました | Credit Suisse | Outperform |
| 2019-07-15 | 開始されました | JP Morgan | Overweight |
すべてを表示
Stoke Therapeutics Inc (STOK) 最新ニュース
Is Stoke Therapeutics Inc. a good long term investmentSuperior return velocity - Autocar Professional
What analysts say about Stoke Therapeutics Inc. stockExtraordinary market timing - Autocar Professional
Stoke Therapeutics Inc. Stock Analysis and ForecastFree Trend-Following Techniques - Autocar Professional
Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome - MSN
Stoke Therapeutics Bets Big On Rare Disease Therapies - Finimize
Stoke Therapeutics Soars 17.02% on Market Optimism - AInvest
What drives Stoke Therapeutics Inc. stock priceRobust investment performance - jammulinksnews.com
Why Stoke Therapeutics Inc. stock attracts strong analyst attentionProven Return Strategy Execution - Newser
Published on: 2025-07-22 13:02:52 - jammulinksnews.com
Jefferies Financial Group Begins Coverage on Stoke Therapeutics (NASDAQ:STOK) - Defense World
How to Take Advantage of moves in (STOK) - news.stocktradersdaily.com
Is Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - 富途牛牛
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - simplywall.st
Stoke Therapeutics (STOK): A High-Conviction Buy with Disease-Modifying Potential in Dravet Syndrome - AInvest
Jefferies Recommends Stoke Therapeutics (STOK) with a Buy Rating - GuruFocus
Jefferies initiates Stoke Therapeutics stock with Buy rating on epilepsy drug potential - Investing.com Canada
Published on: 2025-07-18 11:35:29 - jammulinksnews.com
Stoke Therapeutics’ EMPEROR Study: A New Hope for Dravet Syndrome - TipRanks
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 16, 2025 - BioSpace
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Stoke Therapeutics (STOK) - The Globe and Mail
How Stoke Therapeutics Inc. stock performs during market volatilityProven Trading Plan - Newser
What makes Stoke Therapeutics Inc. stock price move sharplyDaily Price Surge List - Newser
Stoke Therapeutics (NASDAQ:STOK) investors are sitting on a loss of 58% if they invested five years ago - Yahoo Finance
Stoke Therapeutics Inc (STOK) 財務データ
収益
当期純利益
現金流量
EPS
3.32%
1.57%
大文字化:
|
ボリューム (24 時間):